Company Details
Name: Bubble FLO Ltd
Date Founded: 2010
Sector: Life Sciences
Key Products/Services: Bubble FLO® PEP (Positive Expiratory Pressure) Device – a fun, engaging and effective lung clearance device for children.
Website URL: www.bubbleflo.com
Executive Summary
Bubble FLO® is an award-winning MedTech company transforming paediatric respiratory care with the Bubble FLO® PEP (Positive Expiratory Pressure) Device – UKCA and CE marked to make daily airway clearance therapy both effective and enjoyable.
Founded from lived experience, the company addresses a critical gap: NHS-issued equipment is often basic, lacks engagement, and not designed for children.
Since launch, Bubble FLO® has collaborated with leading universities, received support through grants from South of Scotland Enterprise and CPI, won a Scottish EDGE Wild Card, been nominated for Innovator of the Year, and named a finalist for both Business Women Scotland Top 100 Entrepreneurs to Watch and the Female Founder Awards Health category.
Now in its scaling stage, the company is preparing for NHS-led clinical trials at the Royal Hospital for Children in Glasgow while already selling to families across the UK and Europe. With expansion into the US planned within the next year, Bubble FLO® is positioned to set a new standard for paediatric respiratory therapy worldwide.
The Challenge
Children with chronic respiratory conditions such as Cystic Fibrosis, Primary Ciliary Dyskinesia, and Bronchiectasis require daily airway clearance to stay healthy and prevent infections.
Despite this being a lifelong necessity, the equipment typically provided is basic, adult-oriented, and visually unappealing, making it extremely difficult to keep children engaged and motivated.
For families, this turns twice-daily physiotherapy into a stressful battle rather than a manageable routine, often taking a toll on both the child’s confidence and the family’s mental wellbeing.
The lack of dedicated paediatric solutions not only undermines therapy adherence but also directly impacts long-term health outcomes and quality of life. Bubble FLO® set out to change this by addressing the critical gap between clinical effectiveness and child engagement – designing a device that builds an immediate connection with children from the moment it arrives, helping them feel positive about treatment, reducing stress at home, and supporting both physical health and emotional resilience.
The Solution
Bubble FLO® has created the first Positive Expiratory Pressure (PEP) device designed specifically for paediatric users, addressing both medical effectiveness and child engagement.
The device is visually engaging and comes with personalisation stickers, allowing children to make it their own and build a positive connection from the very start.
Bubble FLO® delivers effective lung clearance through a non-siphoning design, ensuring safety and reliability in every use. Families benefit from a product that is easy to set up, use and clean, reducing stress and making twice-daily therapy more manageable. To further support adherence, Bubble FLO® has developed 3D animation videos and a treasure hunt adventure, creating playful resources that guide children through their therapy and keep them motivated. Proudly made in Great Britain, the Bubble FLO® PEP Device combines trusted clinical principles with child-friendly design to transform a medical necessity into an empowering, confidence-building, and fun routine.
The Impact
Bubble FLO® is already making a measurable difference to families and healthcare partners. Parents report that the device transforms chest physiotherapy from a stressful chore into play, with one parent sharing, “Bubble Flo has been absolutely amazing for my 4-year-old… watching him have fun and play with the bubbles while also benefiting his lungs has been such a gift.”
Another family noted that their child, previously resistant to treatment, now asks for their Bubble FLO® almost daily and is far happier to engage in physiotherapy. The company’s innovative approach has also been recognised professionally, with Bubble FLO® featured as an Interface case study for its collaborative development model. Laboratory testing and academic partnerships have already established its clinical effectiveness, and NHS-led clinical trials at the Royal Hospital for Children in Glasgow are now being prepared – an important milestone toward wider clinical adoption and long-term health impact.
Future Plans
Bubble FLO® is focused on scaling impact both clinically and commercially. The company’s immediate priority is to complete NHS-led clinical trials at the RoyalmHospital for Children in Glasgow, generating robust evidence to support broader healthcare adoption. Alongside this, Bubble FLO® will expand its direct-to-family reach across Europe and launch into the US market. Complementary, child- focused products will be introduced on the new website, designed to encourage movement, play, empowerment, and engagement while supporting respiratory health.
Investment opportunities will also be explored to scale operations, accelerate growth, and expand internationally. With these initiatives, Bubble FLO® aims to become the premier brand for paediatric respiratory care, providing innovative, empowering products that improve health outcomes and inspire confidence in children and families worldwide.